Dayle Hogg

Dayle Hogg is an Operating Executive focused on the healthcare sector. He works with new and existing portfolio companies of Abingworth, part of the Carlyle Group, to support their operational capabilities.

Previously, Mr. Hogg was COO of GammaDelta Therapeutics, an Abingworth portfolio company focused on the development of γδ T cell immunotherapies, until its acquisition by Takeda in 2022, when he became Head of Gamma Delta Operations for Takeda. He was also a cofounder of Adaptate Biotherapeutics (also an Abingworth portfolio company and acquired by Takeda in 2022). Mr. Hogg’s prior roles have also included COO of Kesios Therapeutics (an oncology drug development company), investment manager at Touchstone Innovations where he led a number of early-stage investments including Enterprise Therapeutics (potentiator program acquired by Roche) and Storm Therapeutics, and he was a cofounder and Commercial VP of Lectus Therapeutics (programs acquired by UCB).

Mr. Hogg has more than 20 years of experience across a range of functions within the biotechnology sector including within operational, commercial and venture investing roles. He has a degree in Pharmacology from University of Leeds and a PhD in Pharmacology from University of Oxford.